[1] |
Poewe W, Seppi K, Tanner CM, et al. Parkinson disease[J]. Nat Rev Dis Primers, 2017, 3:17013.
doi: 10.1038/nrdp.2017.13
pmid: 28332488
|
[2] |
Li G, Ma J, Cui S, et al. Parkinson′s disease in China: a forty-year growing track of bedside work[J]. Transl Neurodegener, 2019, 8:22.
doi: 10.1186/s40035-019-0162-z
URL
|
[3] |
黄丽芬, 邓子德, 叶晓新, 等. 345例艾滋病死亡病例的医院感染状况分析[J]. 中国感染控制杂志, 2013, 12(3):178-181.
|
|
Deng ZD, Ye XX, et al. Healthcare-associated infection in 345 HIV/AIDS death cases[J]. Chin J Infect Control, 2013, 12(3):178-181.
|
[4] |
Niznik HB, Fogel EF, Fassos FF, et al. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus[J]. J Neurochem, 1991, 56(1):192-198.
pmid: 1987318
|
[5] |
Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson′s-diseased striatum[J]. Synapse, 1991, 9(1):43-49.
pmid: 1796351
|
[6] |
Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice[J]. Mov Disord, 2003, 18(12):1415-1423.
doi: 10.1002/mds.10592
URL
|
[7] |
McHugh PC, Buckley DA. The structure and function of the dopamine transporter and its role in CNS diseases[J]. Vitam Horm, 2015, 98:339-369.
doi: 10.1016/bs.vh.2014.12.009
pmid: 25817874
|
[8] |
Rispoli V, Schreglmann SR, Bhatia KP. Neuroimaging advances in Parkinson′s disease[J]. Curr Opin Neurol, 2018, 31(4):415-424.
doi: 10.1097/WCO.0000000000000584
URL
|
[9] |
Ikeda K, Ebina J, Kawabe K, et al. Dopamine transporter imaging in parkinson disease: progressive changes and therapeutic modification after anti-parkinsonian medications[J]. Intern Med, 2019, 58(12):1665-1672.
doi: 10.2169/internalmedicine.2489-18
URL
|
[10] |
Lee SJ, Oh SJ, Chi DY, et al. One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic solvent system[J]. Nucl Med Biol, 2007, 34(4):345-351.
pmid: 17499723
|
[11] |
Booij J, Tissingh G, Boer GJ, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson′s di-sease[J]. J Neurol Neurosurg Psychiatry, 1997, 62(2):133-140.
doi: 10.1136/jnnp.62.2.133
URL
|
[12] |
Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes[J]. J Neurol Neurosurg Psychiatry, 2013, 84(11):1288-1295.
doi: 10.1136/jnnp-2012-304436
pmid: 23486993
|
[13] |
Palermo G, Giannoni S, Bellini G, et al. Dopamine transporter imaging, current status of a potential biomarker: a comprehensive review[J]. Int J Mol Sci, 2021, 22(20):11234.
doi: 10.3390/ijms222011234
URL
|
[14] |
Chaly T, Dhawan V, Kazumata K, et al. Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography[J]. Nucl Med Biol, 1996, 23(8):999-1004.
pmid: 9004288
|
[15] |
Leung K. N-(3-[(18)F]Fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl)nortropane[M]. Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD): National Center for Biotechnology Information (US), 2004.
|
[16] |
Hong CM, Ryu HS, Ahn BC. Early perfusion and dopamine transporter imaging using 18F-FP-CIT PET/CT in patients with parkinsonism[J]. Am J Nucl Med Mol Imaging, 2018, 8(6):360-372.
|
[17] |
Park HK, Kim JS, Im KC, et al. Functional brain imaging in pure akinesia with gait freezing: [18F] FDG PET and [18F] FP-CIT PET analyses[J]. Mov Disord, 2009, 24(2):237-245.
doi: 10.1002/mds.22347
URL
|
[18] |
陈正平, 吴春英, 张政伟, 等. 多巴胺转运蛋白显像剂18F-FP-β-CIT制备与分布[J]. 中华核医学杂志, 2003, 23(4):241-243.
|
|
Chen ZP, Wu CY, Zhang ZW, et al. Preparation of a dopamine transporter imaging agent 18F-FP-β-CIT and its biodistribution in rat brain[J]. Chin J Nuc Med & Mol Imaging, 2003, 23(4):241-243.
|
[19] |
Lee SJ, Oh SJ, Moon WY, et al. New automated synthesis of [18F]FP-CIT with base amount control affording high and stable radiochemical yield: a 1.5-year production report[J]. Nucl Med Biol, 2011, 38(4):593-597.
doi: 10.1016/j.nucmedbio.2010.11.012
pmid: 21531297
|
[20] |
张晓懿, 朱静, 沈超, 等. 多巴胺转运体显像剂18F-FPCIT的合成与microPET显像[J]. 医药前沿, 2017, 7(36):50-52.
|
|
Zhang XY, Zhu J, Shen C, et al. Synthesis of dopamine transporter imaging agent 18F-FPCIT and its microPET imaging[J]. J Front Med, 2017, 7(36):50-52.
|
[21] |
戴红峰. Tracerlab FX-FN化学合成模块液相转移故障探讨[J]. 化学工程与装备, 2018(10):39-40,63.
|
|
Dai HF. Discussion on liquid phase transfer fault of tra-cerlab FX-FN chemical synthesis module[J]. Fujian Chem Ind, 2018(10):39-40,63.
|
[22] |
Vala C, Mothes C, Chicheri G, et al. Fully automated radiosynthesis of [18F]LBT999 on TRACERlab FX FN and AllinOne modules, a PET radiopharmaceutical for ima-ging the dopamine transporter in human brain[J]. EJNMMI Radiopharm Chem, 2020, 5(1):26.
doi: 10.1186/s41181-020-00105-w
URL
|
[23] |
国家药典委员会. 中华人民共和国药典(第四部)[M]. 北京: 中国医药科技出版社, 2020.
|
|
National Pharmacopoeia Commission. Pharmacopoeia of the People′s Republic of China (the Fourth Part)[M]. Beijing: China Medical Science and Technology Press, 2020.
|
[24] |
Hung JC. Comparison of various requirements of the quality assurance procedures for (18)F-FDG injection[J]. J Nucl Med, 2002, 43(11):1495-1506.
pmid: 12411554
|